

CONTENTS

Chapter	Title	Page No.
	LIST OF FIGURES	v-vii
	LIST OF TABLES	viii-x
	ABBREVIATIONS	xi-xiii
1.	INTRODUCTION	1-19
	1.1 Probiotic lactic acid bacteria (LAB) and human health	1
	1.2 Bacteriocins as microbial warfare agents of probiotic LAB	5
	1.3 Peptic ulcer disease	7
	1.4 Causes of peptic ulcer disease	8
	1.5 Symptoms of peptic ulcer disease	13
	1.6 <i>Helicobacter pylori</i> : Etiologic agent of peptic ulcer disease	15
	1.7 Origin of Problem	18
2.	REVIEW OF LITERATURE	20-81
	2.1 Probiotic lactic acid bacteria and gut physiology	20
	2.2 Health benefits exhibited by probiotic LAB	20
	2.3 Mechanism of probiotic induced bacterial cell lysis	22
	2.4 Probiotics and host immunity	24
	2.5 Genes and proteins supporting probiotic adherence to intestinal epithelium	26
	2.6 Screening of bacteriocin producing probiotic LAB strains	27
	2.7 Classification of bacteriocins produced by probiotic LAB	32
	2.8 Examples of some important LAB bacteriocins	38
	2.9 Antimicrobial spectrum of LAB bacteriocins	46
	2.10 Factors affecting bacteriocin production in LAB	49
	2.11 Gastritis: An inflammatory disease of gastric tissues	50
	2.12 International scenario of the disease	52
	2.13 Indian scenario of the disease	53

2.14	<i>Helicobacter pylori</i> infection and its association with gastric mucosa	56
2.15	Virulence factors of <i>Helicobacter pylori</i>	56
2.16	Induction of cell death signaling by <i>H. pylori</i>	65
2.17	Routes of transmission and detection of peptic ulcers	65
2.18	Antibiotic therapy against peptic ulcer disease	66
2.19	Peptide vaccines available against <i>H. pylori</i>	68
2.20	Emergence of drug resistance in <i>Helicobacter pylori</i>	69
2.21	Probiotics for prevention and treatment of <i>H. pylori</i> Infection	70
2.22	Other applications of bacteriocins producing probiotic LABs	75
3.	MATERIALS AND METHODS	82-139
3.1	Materials used	82
3.2	Composition of the microbiological culture media used	82
3.3	Procurement and maintenance of microbial cultures	89
3.4	Screening, isolation and identification of Anti- <i>Helicobacter pylori</i> bacteriocin producing lactic acid bacterial strain from faecal samples of healthy individual	93
3.4.1	Procurement of faecal samples of healthy subjects	93
3.4.2	Screening and isolation of LAB microflora of the faecal samples	93
3.4.3	Bacteriocin activity assays	93
3.4.4	Identification of the bacteriocin producing Anti- <i>Helicobacter pylori</i> LAB isolate	95
3.4.5	Molecular characterization of the LAB isolate	101
3.5	Production and purification of the bacteriocin at flask level	101
3.5.1	Bacteriocin production studies in MRS medium	101
3.5.2	Optimization of bacteriocin production using Response Surface Methodology (RSM)	103
3.5.3	Purification of the bacteriocin produced by <i>Pediococcus acidilactici</i> BA28	106
3.6	<i>In vitro</i> Characterization of the bacteriocin produced by <i>P. acidilactici</i> BA28	109

3.6.1	Biochemical characterization	109
3.6.2	Molecular weight determination	111
3.6.3	Ionic silver staining	114
3.6.4	Reverse phase HPLC	116
3.6.5	MALDI TOF	119
3.6.6	Antimicrobial spectrum	120
3.6.7	Biopreservative potential and stability of bacteriocin in different model food systems	120
3.6.8	Gene localization studies	121
3.7	Mechanism of bacteriocin action on <i>Helicobacter pylori</i>	135
3.8	SEM analysis of bacteriocin-treated <i>H. pylori</i>	136
3.9	<i>In Vivo</i> therapeutic potential of <i>P. acidilactici</i> BA28 in mice models	136
4.	RESULTS AND DISCUSSION	140-225
4.1	Screening, isolation and identification of Anti- <i>Helicobacter pylori</i> bacteriocin producing lactic acid bacterial strains from faecal samples of healthy individuals	140
4.1.1	Identification of the bacteriocin producing Anti- <i>Helicobacter</i> <i>pylori</i> LAB isolate	142
4.1.2	Molecular characterization of the LAB isolate	151
4.2	Production and purification of the bacteriocin at flask level	154
4.2.1	Bacteriocin production studies	154
4.2.2	Optimization of bacteriocin production using Response Surface Methodology (RSM)	158
4.2.3	Purification of the bacteriocin produced by <i>Pediococcus</i> <i>acidilactici</i> BA28	167
4.3	<i>In vitro</i> characterization of the bacteriocin produced	168
4.3.1	Biochemical characterization	168
4.3.2	Molecular weight determination of the purified bacteriocin	174
4.3.3	Reverse phase HPLC	175
4.3.4	MALDI TOF	176
4.3.5	Antimicrobial spectrum	177

4.3.6	Biopreservation potential and stability of bacteriocin in different model food systems	186
4.3.7	Gene localization studies	200
4.4	Mechanism of bacteriocin action on <i>Helicobacter pylori</i>	214
4.5	SEM analysis of bacteriocin treated <i>H. pylori</i>	217
4.6	<i>In Vivo</i> therapeutic potential of <i>P. acidilactici</i> BA28 in mice models	218
5.	SUMMARY AND CONCLUSION	226-234
6.	REFERENCES	235-294
7.	LIST OF PUBLICATIONS	295
	Annexures	xiv-xviii